ArticleBreast cancer (Tokyo, Japan)2026
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptimal sequencing of antibody-drug conjugates (ADCs) is an important clinical issue in metastatic breast cancer. However, data on datopotamab deruxtecan (Dato-DXd) following trastuzumab deruxtecan (T-DXd) have not been reported. This study evaluated real-world outcomes of Dato-DXd in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, focusing on prior T-DXd exposure.
methodsThis single-center retrospective study included patients who received at least one dose of Dato-DXd by December 2025. Outcomes were evaluated overall and by prior T-DXd exposure. Endpoints included disease control rate (DCR), objective response rate (ORR), time to treatment failure (TTF), and progression-free survival (PFS). Among patients who received prior T-DXd, TTF with T-DXd and subsequent Dato-DXd was compared.
resultsA total of 45 patients were analyzed: 19 had prior T-DXd exposure and 26 were T-DXd-naïve. The cohort was heavily pretreated with a median of six prior treatment lines and three prior chemotherapy regimens for metastatic disease. Overall, the DCR and ORR were 57.8% and 24.4%, respectively; the corresponding rates were 52.6% and 10.5% in the prior T-DXd group and 61.5% and 34.6% in the T-DXd-naïve group. The median TTF and PFS were 4.2 and 4.1 months in the overall cohort, and 3.4 and 3.0 months in the prior T-DXd group, respectively. Among 16 patients evaluable for TTF with both agents, five (31.3%) had a longer TTF with Dato-DXd than with prior T-DXd.
conclusionsDato-DXd showed limited but clinically relevant activity, including after prior T-DXd. Further studies are needed to optimize ADC sequencing.
Indexed as
Identifiers
42684568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.